GlassScriptPhysician profile
Alexis Katz
NPI 1194102756
$5,028.49
in general payments reported to CMS, 2019-2025
29 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.01 · 2021: $901 · 2022: $1,202 · 2023: $1,474 · 2024: $1,317 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.36 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,147.76 | 2021-2025 | |
| Janssen Biotech, INC. | $576.48 | 2021-2024 | Tremfya |
| Amgen INC. | $552.72 | 2021-2024 | Prolia, Evenity, Krystexxa |
| Novartis Pharmaceuticals Corporation | $514.19 | 2021-2024 | |
| Ucb, INC. | $419.28 | 2021-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $331.67 | 2021-2024 | Orencia |
| Glaxosmithkline, LLC. | $265.69 | 2021-2024 | Nucala, Benlysta |
| Radius Health, INC. | $174.93 | 2021-2024 | Tymlos |
| Alvogen INC | $161.59 | 2022-2023 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.54 | 2023-2024 | Ofev, Cyltezo |
| Pfizer INC. | $114.77 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $82.82 | 2022-2024 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $76.44 | 2021-2024 | Acthar |
| Lilly USA, LLC | $69.01 | 2021-2023 | Taltz |
| Fresenius Kabi USA, LLC | $60.76 | 2023-2024 | Idacio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $54.81 | 2022-2023 | Opsumit |
| Horizon Therapeutics Plc | $41.34 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $34.41 | 2023 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $32.31 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $29.32 | 2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $24.09 | 2025 | |
| Sobi, INC | $21.93 | 2024 | |
| Merck Sharp & Dohme LLC | $20.44 | 2025 | Keytruda |
| Kiniksa Pharmaceuticals International, Plc | $19.60 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $19.08 | 2024 | |
| Organon LLC | $18.75 | 2022 | |
| Merz Pharmaceuticals, LLC | $17.51 | 2025 | Inbrija |
| Cumberland Pharmaceuticals, INC. | $16.24 | 2022 | |
| Mallinckrodt Enterprises LLC | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.